

**North Ottawa  
Community Hospital**

*An Affiliate of North Ottawa Community Health System*

November 23, 2004

UNITED STATES NUCLEAR REGULATORY COMMISSION  
Region III, Materials Licensing Section  
2443 Warrenville Road, Suite 210  
Lisle, IL 60532-4352

**RE: Amendment to License No. 21-13963-01, North Ottawa Community Hospital.**

**If possible, please expedite this amendment. We will be replacing our Radiation Safety Officer and ALL authorized users on January 15, 2005.**

Please amend our license as follows:

1. Remove Jeffery S. Tanis, M.D. as Radiation Safety Officer. As of January 15, 2005 he will no longer be at this facility.
2. Remove the following authorized users. As of January 15, 2005 they will no longer be at this facility.

Jeffery S. Tanis, M.D.  
J. Kellaway, M.D.  
Frederick Jay Kellaway, M.D.  
John Thomas Jones, M.D.

3. Add Michael A. Schmidt, M.D. as Radiation Safety Officer. He is currently listed on license number 21-02187-01, Mercy Hospital. A copy of that license is enclosed for your review.
4. Add the following authorized users. They are all currently listed on license number 21-02187-01, Mercy Hospital. A copy of that license is enclosed for your review.

UNITED STATES NUCLEAR REGULATORY COMMISSION

November 23, 2004

Page 2

Ronald L. Stuk, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
Gregory A. Bernath, M.D.	10 CFR 35.100 and 35.200 (limited to cardiovascular clinical procedures).
Thomas J. Hill, M.D.	10 CFR 35.100 and 35.200 (limited to cardiovascular clinical procedures).
Carl J. Gebuhr, M.D.	10 CFR 35.100 and 35.200 (limited to cardiovascular clinical procedures).
Mark E. Meengs, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures).
Robert J. Fles, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
Ralph G. Ryan, M.D.	10 CFR 35.100 and 35.200 (limited to cardiovascular clinical procedures).
Dan West, M.D.	10 CFR 35.200 (limited to cardiovascular clinical procedures).
Darryl R. Stevens, D.O.	10 CFR 35.100 and 35.200
John David Kaurich, M.D.	10 CFR 35.100 and 35.200
David L. Kaufman, M.D.	10 CFR 35.100 and 35.200
Osama Al-Bawab	10 CFR 35.100 and 35.200 (limited to cardiovascular clinical procedures).
Michael A. Schmidt, M.D.	10 CFR 35.100 and 35.200
Jeffery L. Stuk, D.O.	10 CFR 35.100 and 35.200
Joseph John Marous, III, M.D.	10 CFR 35.100 and 35.200

Thank you for your cooperation in this matter. If you have any questions, please contact our consulting physicist, Dawn Edwards at 734-662-3197.

Sincerely,




David VanderVeen  
Vice President, Operations  
North Ottawa Community Hospital  
616-847-5235  
Email-dvanderveen@noch.org

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <ol style="list-style-type: none"> <li>Mercy Hospital Department of Radiology</li> <li>and Clinical Laboratory 1500 East Sherman Blvd. Muskegon, MI 49443</li> </ol>	<p>In accordance with letter dated March 5, 2004,</p> <ol style="list-style-type: none"> <li>License number 21-02187-01 is amended in its entirety to read as follows:</li> <li>Expiration date March 31, 2005</li> </ol> <p>Pocket No. 030-02016 Reference No.</p>
--	---

<ol style="list-style-type: none"> <li>Byproduct, source, and/or special nuclear material                     <ol style="list-style-type: none"> <li>Any byproduct material permitted by 10 CFR 35.100</li> <li>Any byproduct material permitted by 10 CFR 35.200</li> <li>Any byproduct material permitted by 10 CFR 35.300</li> <li>Any byproduct material identified in 10 CFR 35.500</li> <li>Any byproduct material permitted by 10 CFR 31.11</li> </ol> </li> </ol>	<ol style="list-style-type: none"> <li>Chemical and/or physical form                     <ol style="list-style-type: none"> <li>Any</li> <li>Sealed sources identified in 10 CFR 35.500</li> <li>Prepackaged Kits</li> </ol> </li> </ol>	<ol style="list-style-type: none"> <li>Maximum amount that licensee may possess at any one time under this license                     <ol style="list-style-type: none"> <li>As needed</li> <li>As needed</li> <li>As needed</li> <li>2 sources not to exceed 1 Curie each</li> <li>As needed</li> </ol> </li> </ol>
---	--	---



<ol style="list-style-type: none"> <li>Authorized Use:                     <ol style="list-style-type: none"> <li>Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</li> <li>Any imaging and localization study permitted by 10 CFR 35.200.</li> <li>Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma therapy).</li> </ol> </li> </ol>
---

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-02187-01

Docket or Reference Number  
030-02016

Amendment No. 36

D. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

E. In vitro studies.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1500 East Sherman Boulevard, Muskegon, Michigan.
11. The Radiation Safety Officer for this license is Robert J. Fles, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:
- Ronald L. Stuk, M.D. 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, and 31.11.
- Gregory A. Bernath, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Thomas J. Hill, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Carl J. Gebuhr, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Mark E. Meengs, M.D. 10 CFR 35.200 limited to cardiovascular clinical procedures.
- Robert J. Fles, M.D. 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, and 31.11.
- Ralph G. Ryan, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Dan West, M.D. 10 CFR 35.200 limited to cardiovascular clinical procedures.
- Darryl R. Stevens, D.O. 10 CFR 35.100 and 35.200 and 31.11.
- John David Kaurich, M.D. 10 CFR 35.100 and 35.200 and 31.11.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-02187-01

Docket or Reference Number  
030-02016

Amendment No. 36

- David L. Kaufman, M.D. 10 CFR 35.100 and 35.200 and 31.11.
- Osama Al-Bawab, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Michael A. Schmidt, M.D. 10 CFR 35.100 and 35.200.
- Jeffery L. Stuk, D. O. 10 CFR 35.100 and 35.200.
- Joseph John Marous, III, M.D. 10 CFR 35.100 and 35.200.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(a) for establishing decommissioning financial assistance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. Except as specifically provided otherwise, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, the license condition does not limit the licensee's ability to make changes to its program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application received August 10, 1994.

B. Letter dated February 14, 1995.


FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date APR 09 2004

By Toye L. Simmons  
Toye L. Simmons  
Materials Licensing Section  
Region III

**FROM:**  
SHERRY TRAVIS  
(616) 842-3600  
NORTH OTTAWA COMMUNITY HOSPITAL  
1309 SHELDON RD.  
GRAND HAVEN MI 49417

1 LBS 1 OF 1



**IL 603 9-03**



**SHIP TO:**

REGION III, OFFICE OF MATLS. LICENS  
UNITED STATES NUCLEAR REG. COMM.  
STE. 210  
2443 WARRENVILLE ROAD  
**LISLE IL 60532-4352**

**UPS GROUND**

TRACKING #: 1Z 464 443 03 4012 2925



BILLING: P/P

1716 REV 398